FGGY
FGGY carbohydrate kinase domain-containing protein
Also known as: FGGY_HUMAN, FLJ10986
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q96C11
- Gene
- FGGY
- Ensembl
- ENSG00000172456
- Chromosome
- 1
- Canonical length
- 551 aa
- Protein class
- Disease related genes, Enzymes, Metabolic proteins, Potential drug targets, Predicted intracellular proteins
- Subcellular location
- Nucleoplasm,Nuclear bodies
OverviewNCBI Gene
This gene encodes a protein that phosphorylates carbohydrates such as ribulose, ribitol, and L-arabinitol. Genome-wide association studies in some populations have found an association between polymorphisms in this gene and sporadic amyotrophic lateral sclerosis, but studies of other populations have not been able to replicate this association. Alternative splicing results in multiple transcript variants. [provided by RefSeq, May 2013]
Canonical amino-acid sequenceUniProt
551 residues, UniProt reviewed canonical sequence.
>Q96C11|FGGY
1 MSGGEQKPER YYVGVDVGTG SVRAALVDQS GVLLAFADQP IKNWEPQFNH HEQSSEDIWA
61 ACCVVTKKVV QGIDLNQIRG LGFDATCSLV VLDKQFHPLP VNQEGDSHRN VIMWLDHRAV
121 SQVNRINETK HSVLQYVGGV MSVEMQAPKL LWLKENLREI CWDKAGHFFD LPDFLSWKAT
181 GVTARSLCSL VCKWTYSAEK GWDDSFWKMI GLEDFVADNY SKIGNQVLPP GASLGNGLTP
241 EAARDLGLLP GIAVAASLID AHAGGLGVIG ADVRGHGLIC EGQPVTSRLA VICGTSSCHM
301 GISKDPIFVP GVWGPYFSAM VPGFWLNEGG QSVTGKLIDH MVQGHAAFPE LQVKATARCQ
361 SIYAYLNSHL DLIKKAQPVG FLTVDLHVWP DFHGNRSPLA DLTLKGMVTG LKLSQDLDDL
421 AILYLATVQA IALGTRFIIE AMEAAGHSIS TLFLCGGLSK NPLFVQMHAD ITGMPVVLSQ
481 EVESVLVGAA VLGACASGDF ASVQEAMAKM SKVGKVVFPR LQDKKYYDKK YQVFLKLVEH
541 QKEYLAIMND DLocalizationUniProt · AlphaFold · HPA
Whether an antibody against FGGY can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Intracellular
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.21
- Highest tissue expression
- 71 nTPM
Expression across tissuesHPA
Tissue
- liver: 71 nTPM
- skeletal muscle: 39 nTPM
- epididymis: 35 nTPM
- kidney: 18 nTPM
- tongue: 16 nTPM
- adrenal gland: 14 nTPM
Single-cell type
- thymic myoid cells: 806 nCPM
- proximal tubule cells: 779 nCPM
- myonuclei: 527 nCPM
- cholangiocytes: 496 nCPM
- hepatocytes: 332 nCPM
- neutrophils: 279 nCPM
Immune cell
- memory B-cell: 5.1 nTPM
- naive CD8 T-cell: 4.3 nTPM
- memory CD8 T-cell: 3.8 nTPM
- naive B-cell: 3.6 nTPM
- non-classical monocyte: 3.4 nTPM
- gdT-cell: 3 nTPM
Brain region
- cerebellum: 46 nTPM
- thalamus: 35 nTPM
- midbrain: 28 nTPM
- pons: 27 nTPM
- medulla oblongata: 27 nTPM
- basal ganglia: 26 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about FGGY.
Disease | AllUniProt
Conditions FGGY is implicated in, by any mechanism.
- Amyotrophic lateral sclerosis (ALS) MIM:105400
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 1.22
- gnomAD pLI
- 0
- gnomAD missense Z
- -0.12
- DepMap mean gene effect
- 0.19
- DepMap dependency class
- none
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
Molecular functions
- D-ribulokinase activity
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads FGGY as an antibody target. Whether an autoantibody or antibody against FGGY could matter depends on whether native FGGY is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
FGGY is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label FGGY as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...